Enhancing the tolerability of tacrine with propantheline.
Faber
R A
RA
Negro
P J
PJ
D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy*; D018680:Cholinergic Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005767:Gastrointestinal Diseases / Q000139:chemically induced* / Q000517:prevention & control*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011413:Propantheline / Q000008:administration & dosage / Q000627:therapeutic use*; D013619:Tacrine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use
D018680:Cholinergic Antagonists; D002800:Cholinesterase Inhibitors; D011413:Propantheline; D013619:Tacrine